Delivery Order SPE2DB24D2205-SPE2DB25FEFCZ
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Xolair 150 mg/ml syringes, with a contract ceiling value of $5,402.58 and an ultimate completion date of August 19, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion pharmaceutical supply vehicle...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of XOLAIR 150 mg/ml syringes, with a contract ceiling value of $5,762.72 and an ultimate completion date of August 19, 2025. This firm fixed-price delivery order represents a competitively awarded contract with no set-aside designation, performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract falls under AmerisourceBergen's broader...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Xolair 300 mg/2 mL auto-injectors with a ceiling value of $3,188.32. This firm fixed-price, competitively awarded delivery order is scheduled for completion by August 21, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a single delivery order issued under AmerisourceBergen's larger indefinite delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Xolair 150 mg/mL syringes, valued at $10,805.10. This is a firm fixed-price delivery order with a completion date of August 20, 2025, and will be performed at the contractor's Conshohocken, Pennsylvania facility. The award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's proven capability to meet federal pharmaceutical procurement...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Xolair 300 mg/2 mL syringes on August 7, 2025, with a ceiling value of $1,732.19 and an ultimate completion date of August 28, 2025. This firm fixed-price delivery order represents a competitive, non-set-aside award and is performed from the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $4,905.08 to AmerisourceBergen Drug Corp for the supply of Xolair 300 mg/2 ml syringes on July 31, 2025, with an ultimate completion date of August 21, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The product will be delivered to the company's corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Xolair 300 mg/2 ml auto-injector doses with a ceiling value of $1,594.16 and a firm fixed price arrangement. The contract, which represents a non-set-aside, competitively awarded procurement, is scheduled for ultimate completion by August 26, 2025. This delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order valued at $21,610.20 to AmerisourceBergen Drug Corp for XOLAIR 150 mg/mL syringes on August 13, 2025, with an ultimate completion date of September 4, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside contract fulfilling pharmaceutical supply requirements for federal medical procurement. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Xolair 150 mg/mL syringes, valued at $2,161.02, with an ultimate completion date of August 22, 2025. This contract was awarded on August 1, 2025, under a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a delivery order valued at $25,932.24 to AmerisourceBergen Drug Corp for the supply of Xolair 150 mg/mL syringes. This competitively awarded, firm fixed-price contract is scheduled for completion by August 21, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FEFCZDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Xolair 75 mg/0.5 ml syringes with a ceiling value of $1,080.54 and a firm fixed price structure. This delivery order is non-set-aside and represents a competitively awarded contract with an ultimate completion date of August 11, 2025. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp, one of the nation's leading pharmaceutical distributors and healthcare solutions providers, serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The company's contract portfolio with the Defense Logistics Agency encompasses a wide range of pharmaceutical products and medical supplies spanning multiple therapeutic domains, from specialty medications to vaccines and medical devices. This specific delivery order for Xolair—a biologic immunosuppressant used in treating moderate-to-severe asthma and chronic urticaria—exemplifies AmerisourceBergen's role in supporting the Defense Health Agency and other federal healthcare systems through its flexible and comprehensive contracting vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 7/21/25 |